Wide Ranks

ABBV

AbbVie Inc.

183.08

Top Statistics
Market Cap 323 B Forward PE 15.07 Revenue Growth 3.80 %
Current Ratio 0.65 Trailing PE 63.79 Earnings Growth -12.30 %
Profit Margins 9.22 % Peg Ratio Dividend Yield 3.58 %
Enterprice / EBITA 15.12 Enterprise / Revenue 6.98 Price To Sales Trailing12 Months 5.83
Profitability
Profit Margins 9.22 % Operating Margins 28.93 %
Balance Sheet
Total Cash 7 B Total Cash Per Share 4.12 Total Debt 71 B
Total Debt To Equity 1174.82 Current Ratio 0.65 Book Value Per Share 3.41
All Measures
Return On Equity 0.5641 Total Debt 71 B Beta 0.6130
Fifty Two Week Low 138.01 Audit Risk 2 Target Mean Price 204.74
Short Percent Of Float 0.0114 Trailing Peg Ratio 43.73 % Last Fiscal Year End 1 B
Average Volume10days 8 M Next Fiscal Year End 1 B Held Percent Insiders 0.0010
Ebitda Margins 46.15 % Trailing PE 63.79 Most Recent Quarter 1 B
Gmt Off Set Milliseconds -18000000 Fifty Day Average 188.64 Open 181.14
State IL Return On Assets 0.0772 Time Zone Short Name EST
Board Risk 5 Trailing Eps 2.87 Day Low 180.89
Shares Outstanding 1 B Compensation Risk 2 Price Hint 2
Website https://www.abbvie.com 52 Week Change 0.2858 Recommendation Key buy
Quick Ratio 43.60 % Is_sp_500 True Profit Margins 9.22 %
Debt To Equity 1174.82 Fifty Two Week High 207.32 Enterprise To Revenue 6.98
Operating Cashflow 16 B Five Year Avg Dividend Yield 416.00 % Market Cap 323 B
Quote Type EQUITY Industry Drug Manufacturers - General Ex Dividend Date 1 B
Overall Risk 6 Long Name AbbVie Inc. Current Ratio 0.65
Number Of Analyst Opinions 29 Governance Epoch Date 1 B Forward PE 15.07
Regular Market Volume 4 M Short Ratio 292.00 % Message Board Id finmb_141885706
Shares Short Prior Month 16 M City North Chicago Uuid 73238d42-cdcc-3f92-8141-dd675addae10
Previous Close 181.14 First Trade Date Epoch Utc 1 B Book Value 3.41
Volume 4 M Price To Book 53.64 Total Cash Per Share 4.12
Total Revenue 55 B Shares Short Previous Month Date 1 B Target Median Price 208.00
Max Age 86400 Recommendation Mean 1.83 Sand P52 Week Change 0.3133
Operating Margins 28.93 % Last Dividend Value 1.55 Net Income To Common 5 B
Ask 183.31 Implied Shares Outstanding 1 B Average Daily Volume10 Day 8 M
Total Cash 7 B Revenue Per Share 31.40 Dividend Rate 6.56
Date Short Interest 1 B Share Holder Rights Risk 9 Regular Market Previous Close 181.14
Target Low Price 165.00 Free Cashflow 17 B Dividend Yield 3.58 %
Target High Price 240.00 Address1 1 North Waukegan Road Trailing Annual Dividend Rate 6.20
Average Volume 5 M Earnings Quarterly Growth -12.20 % Forward Eps 12.13
Compensation As Of Epoch Date 1 B Regular Market Day High 184.24 Day High 184.24
Shares Short 20 M Regular Market Open 181.14 Industry Key drug-manufacturers-general
Bid 182.00 Earnings Growth -12.30 % Revenue Growth 3.80 %
Shares Percent Shares Out 0.0114 Currency USD Time Zone Full Name America/New_York
Is_nasdaq_100 False Zip 60064-6400 Payout Ratio 213.59 %
Regular Market Day Low 180.89 Held Percent Institutions 0.7340 Current Price 183.08
Enterprise To Ebitda 15.12 Financial Currency USD Trailing Annual Dividend Yield 3.42 %
Gross Margins 70.34 % Industry Disp Drug Manufacturers - General Country United States
Float Shares 1 B Two Hundred Day Average 178.97 Enterprise Value 387 B
Price To Sales Trailing12 Months 5.83 Last Dividend Date 1 B Ebitda 25 B
Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.

The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.

In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products.

Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism.

It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP.

The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.